$CDNA News

HC Wainwright & Co. Reiterates Neutral on CareDx, Maintains $46 Price Target

CareDx, Inc. (CDNA) Q2 2026 Earnings Call Transcript

CareDx, Inc. 2026 Q2 - Results - Earnings Call Presentation

CareDx Q2 Adj. EPS $0.37 Beats $0.23 Estimate, Sales $131.948M Beat $114.044M Estimate

CareDx Raises FY2026 Sales Guidance from $447.000M-$465.000M to $490.000M-$500.000M vs $455.924M Est

CareDx's Growth Prospects With Naveris Keep Me Bullish

Why Is CareDx Stock Skyrocketing Thursday?

CareDx shares jump as Medicare finalizes transplant testing coverage policy (CDNA)

BTIG Maintains Buy on CareDx, Raises Price Target to $45

CareDx to Report Second Quarter 2026 Financial Results on July 30, 2026

CareDx Announces Finalization of Solid Organ Transplant Molecular Testing Local Coverage Determination

CareDx Finalizes Medicare Local Coverage Determination Procedure Regarding Molecular Testing For Solid Organ Allograft Rejection

CareDx: The Transplant Platform Is Becoming A Specialty Diagnostics Compounder

CareDx Completes Acquisition of Naveris, Extending Leadership into High-Growth Specialty Oncology

Eurobio Scientific finalizes the acquisition of CareDX’s transplant Lab Product division

CareDx Announces Completion of Sale of Lab Products Business to Eurobio Scientific

CareDx Completes Sale Of Its Lab Products Operations To Eurobio Scientific For $171.2M

CareDx's CEO Sells 17K Shares

CareDx (NASDAQ:CDNA) Passes Both the Minervini Trend Template and High Growth Momentum Tests

CareDx (CDNA) Moves 11.5% Higher: Will This Strength Last?